Ripk2 - receptor-interacting serine-threonine kinase 2 Gene

Species: Rattus norvegicus

Gene Type: protein coding
Gene ID: 362491

About Ripk2

Primary_assembly 5: 29,631,570-29,662,657 reverse strand.mRatBN7.2:CM026978.1

This gene has 1 transcript (splice variant), 207 orthologues, 23 paralogues and is associated with 1 phenotype. Biased expression in Heart (RPKM 72.), Spleen (RPKM 64.7) and 9 other tissues.

Summary

Predicted to enable several functions, including JUN kinase kinase kinase activity; Caspase binding activity; and protein domain specific binding activity. Predicted to be involved in several processes, including cellular response to muramyl dipeptide; positive regulation of cellular protein metabolic process; and positive regulation of interleukin-1 beta production. Predicted to act upstream of or within several processes, including immune response-regulating signaling pathway; positive regulation of cytokine production; and response to bacterium. Predicted to be located in cytoskeleton; cytosol; and vesicle. Predicted to be part of protein-containing complex. Orthologous to human RIPK2 (receptor interacting serine/threonine kinase 2). [provided by Alliance of Genome Resources, Apr 2022]

Ripk2 Products (2)

mRNA Protein Name
NM_001191865.1 NP_001178794.1 receptor-interacting serine/threonine-protein kinase 2
NM_001191865.1 NP_001178794.1 receptor-interacting serine/threonine-protein kinase 2

Ripk2 Protein Structure

STKc_RIP2

STKc_RIP2: cd14026 (19 - 302)

CARD_RIP2_CARD3

CARD_RIP2_CARD3: cd08786 (436 - 522)

  • 0
  • 100
  • 200
  • 300
  • 400
  • 500
  • 539 a.a.
Protein Preferred Names Protein Names

receptor-interacting serine/threonine-protein kinase 2

  • receptor (TNFRSF)-interacting serine-threonine kinase 2

Related Agents

  • Clinical Phase
  • Pre-clinical Phase

Clinical Phase

Bioactive Molecules (4)
Art. -Nr. Produktname Wirkung
Reinheit Phase
HY-157442 GLPG3312 Inhibitor 98.63% Phase 1
HY-112038A GSK2983559 Inhibitor 99.49% Phase 1
HY-19764 GSK2983559 active metabolite Inhibitor 98.86% Phase 1
HY-112038 GSK2983559 free acid Inhibitor 99.49% Phase 1

Pre-clinical Phase

Bioactive Molecules (18)
Art. -Nr. Produktname
Wirkung
Reinheit
Rare Diseases
HY-18937 WEHI-345 Inhibitor 99.29% Unkown
HY-111866 PROTAC RIPK degrader-2 Inhibitor 99.89% Unkown
HY-107978 RIPK-IN-4 Inhibitor 99.57% Unkown
HY-19628 OD36 Inhibitor 99.33% Unkown
HY-122665 HTH-01-091 Inhibitor 99.81% Unkown
HY-115630 cRIPGBM chloride 99.82% Unkown
HY-100112 WEHI-345 analog Inhibitor 98.41% Unkown
HY-19628A OD36 hydrochloride Inhibitor / Unkown
HY-125466 cRIPGBM / Unkown
HY-184001 LT-1339-553 Inhibitor / Unkown
HY-123924 CSLP37 Inhibitor / Unkown
HY-171592 RIPK2-IN-7 Inhibitor / Unkown
HY-147235 PROTAC RIPK2 Degrader-1 Inhibitor / Unkown
HY-123925 CSLP43 Inhibitor / Unkown
HY-159965 NOD1-RIPK2-IN-1 Inhibitor / Unkown
HY-136010 RIP2 Kinase Inhibitor 4 Inhibitor / Unkown
HY-173454 RIPK2/3-IN-2 Inhibitor 99.67% Unkown
HY-175026 RIPK2-IN-8 Inhibitor / Unkown

Orthologs Information

Species Symbol Source ID
Homo sapiens Ripk2 NCBI NCBI:8767